Pathstone Family Office’s Acumen Pharmaceuticals ABOS Stock Holding History

Pathstone Family Office’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$1.99M	Buy	478,790 +11,730	+3%	+$72.5K	0.02%	476
2023 Q2	$2.25M	Buy	467,060 +75,000	+19%	+$359K	0.03%	297
2023 Q1	$1.59M	Sell	392,060 -138,270	-26%	-$722K	0.03%	332
2022 Q4	$2.86M	Buy	530,330 +277,060	+109%	+$1.86M	0.05%	240
2022 Q3	$2.54M	Buy	+253,270	New	+$1.45M	0.05%	211

Other funds holding ABOS

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Sands Capital Ventures Arlington, Virginia $695M AUM 31.12% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Knollwood Investment Advisory Hunt Valley, Maryland $1.18B AUM 37.58% 1-Year Est. Return

Pathstone Family Office's ABOS Position: Q3 2023 in Review

Pathstone Family Office increased its Acumen Pharmaceuticals (ABOS) stake by 2.5% in Q3 2023, buying an estimated $72.5K and bringing the position to 478,790 shares worth $1.99M. The position accounts for 0.02% of the portfolio, ranked #476.

Pathstone Family Office first reported a position in ABOS in Q3 2022 and has held it in 5 quarters since. The position peaked at $2.86M in Q4 2022. 66 funds tracked by Wall St. Rank hold ABOS as of Q3 2023.

Pathstone Family Office held 478,790 shares of Acumen Pharmaceuticals worth $1.99M as of Q3 2023.
Pathstone Family Office bought 11,730 Acumen Pharmaceuticals shares in Q3 2023, an estimated $72.5K.
Acumen Pharmaceuticals made up 0.02% of Pathstone Family Office's portfolio in Q3 2023, its #476 holding.
Pathstone Family Office first reported a position in Acumen Pharmaceuticals in Q3 2022 and has held it in 5 quarters since.
Pathstone Family Office's Acumen Pharmaceuticals position peaked at $2.86M in Q4 2022.
66 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.